Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies

A method of treating a subject having a non-Hodgkin's lymphoma (NHL) comprising subcutaneously administering to the subject mosunetuzumab in a dosing regimen comprising eight dosing cycles, wherein:

• (a) the first dosing cycle comprises a first subcutaneous dose (C1D1), a second subcutaneous dose (C1D2), and a third subcutaneous dose (C1D3) of mosunetuzumab, wherein:
• (i) the C1D1 is 5 mg;
• (ii) the C1D2 is 45 mg;
• and
• (iii) the C1D3 is 45 mg;
• and
• (b) the second to eighth dosing cycles each comprises a single subcutaneous dose (C2D1-C8D1) of mosunetuzumab, wherein each of the C2D1-C8D1 of mosunetuzumab is 45 mg,
• wherein the eight cycles are 21-day dosing cycles;
• or the first dosing cycle is a 21-day dosing cycle and the second to eighth dosing cycles are 28-day dosing cycles, and wherein the method comprises administering to the subject the C1D1, the C1D2, and the C1D3 on or about Days 1, 8, and 15, respectively, of the first dosing cycle and administering to the subject the C2D1-C8D1 on Day 1 of each of the second to eighth dosing cycles.